<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805803</url>
  </required_header>
  <id_info>
    <org_study_id>ID RCB: 2015-A01702-47</org_study_id>
    <nct_id>NCT02805803</nct_id>
  </id_info>
  <brief_title>Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.</brief_title>
  <acronym>PSA-QOL</acronym>
  <official_title>Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Diaconesses Croix Saint-Simon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Diaconesses Croix Saint-Simon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prosthetic joint infection (PJI) management is complex and requires prosthesis replacement&#xD;
      when symptoms duration is greater than 30 days or debridement with modular set replacement&#xD;
      when symptoms duration is lesser than one month. Nevertheless, the prolonged suppressive&#xD;
      antibiotherapy (PSA) is the single treatment we can provide to high risk surgical patients&#xD;
      and those who refuse reoperation.&#xD;
&#xD;
      There is limited data available on PSA modality, its tolerance and efficacy, this lack of&#xD;
      data motivated us to concept a prospective study of long term patient follow up with PJI&#xD;
      treated with prolonged suppressive antibiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective:&#xD;
&#xD;
      Quality of life assessment of patients undergoing prolonged suppressive antibiotherapy for&#xD;
      PJI.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. Depressive symptoms assessment in patients undergoing prolonged suppressive&#xD;
           antibiotherapy for PJI.&#xD;
&#xD;
        2. Functional assessment in patients undergoing prolonged suppressive antibiotherapy for&#xD;
           PJI.&#xD;
&#xD;
        3. Evaluation of PSA side effects&#xD;
&#xD;
        4. Evaluation of nutritional status&#xD;
&#xD;
        5. Evaluation of of PSA termination criteria&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      The follow up oh this cohort will be conducted using 3 questionaries related to quality of&#xD;
      life, joint stiffness and depressive symptoms.&#xD;
&#xD;
      Study type:&#xD;
&#xD;
      This is a study of health care procedure, evaluating the quality of life of patients&#xD;
      undergoing prolonged suppressive antibiotherapy for PJI.&#xD;
&#xD;
      Sample size: all patients cared by our referral center of bone and joint infection, who meet&#xD;
      protocol selection criteria will be included in the study, thus we are expecting to recruit&#xD;
      60 patients.&#xD;
&#xD;
      Study duration: 6 years.&#xD;
&#xD;
      Recruitment period: 4 years.&#xD;
&#xD;
      Maximal duration of data collection: 2 years.&#xD;
&#xD;
      Investigator center: Single center study.&#xD;
&#xD;
      Mean patient inclusion per year: 15 patients per year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life assessment of patients undergoing prolonged suppressive antibiotherapy for PJI.</measure>
    <time_frame>2 years</time_frame>
    <description>Method assessment : Short Form 12 questionary (SF12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Depressive symptoms assessment in patients undergoing prolonged suppressive antibiotherapy for PJI.</measure>
    <time_frame>2 years</time_frame>
    <description>Method assessment : Beck depression inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Functional assessment in patients undergoing prolonged suppressive antibiotherapy for PJI.</measure>
    <time_frame>2 years</time_frame>
    <description>Method assessment : Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Evaluation of PSA side effects</measure>
    <time_frame>2 years</time_frame>
    <description>Method assessment : anamnesis and clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Evaluation of nutritional status</measure>
    <time_frame>2 years</time_frame>
    <description>Method assessment : BMI and proteinuria measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Evaluation of PSA termination criteria</measure>
    <time_frame>2 years</time_frame>
    <description>Monitoring :&#xD;
Treatment failure in case of :&#xD;
Side effects&#xD;
Relapse of the infection&#xD;
Persistance of the infection&#xD;
The patient wishes terminate the treatment because of :&#xD;
Side effects&#xD;
The infection is controlled</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Quality of life questionary</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:&#xD;
SF12&#xD;
Beck&#xD;
WOMAC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionary</intervention_name>
    <description>Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.</description>
    <arm_group_label>Quality of life questionary</arm_group_label>
    <other_name>Depressive symptoms questionary</other_name>
    <other_name>Joint functional questionary</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged over 18 years old with hip or knee prosthetic infection who consented to&#xD;
             participate in the study&#xD;
&#xD;
          -  Non-eligible patient to surgical treatment&#xD;
&#xD;
          -  Patient eligible to prolonged suppressive antibiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient who does not meet eligibility criteria&#xD;
&#xD;
          -  Patient living or traveling abroad for whom 2 years minimum follow up is impossible.&#xD;
&#xD;
          -  Patient lawfully deprived of his liberty&#xD;
&#xD;
          -  Patient not insured under social security scheme&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VANINA MEYSSONNNIER, Doctorate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Diaconesses Croix Saint-Simon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Younes KERROUMI, Doctorate</last_name>
    <phone>(+33) 1 44 64 33 84</phone>
    <email>ykerroumi@hopital-dcss.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Dianconesses croix saint Simon</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Younes KERROUMI, Doctorate</last_name>
      <phone>01 44 64 33 84</phone>
      <email>ykerroumi@hopital-dcss.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Diaconesses Croix Saint-Simon</investigator_affiliation>
    <investigator_full_name>VANINA MEYSSONNIER</investigator_full_name>
    <investigator_title>Infectious deseases specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

